The cancer originated from large bowel represents a widespread cancer along the
world and a considerable percentage of new cases are diagnosed with distant disease. Recently,
the detection of “clever” medicaments such as focused therapy was the outcome of
an improved comprehension of the procedures that transform physiological tissues to tumor. The family of
focused medication includes medicaments that specifically affect specific molecular routes implicated in the
production of the tumor and its development. The new natural substances aim at inhibiting the procedure of
angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis
and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents
vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy
for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February
26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to
considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as
primary therapy in patients with large bowel tumor and distant metastases is analysed.
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Rights & PermissionsPrintExport